| treatment |
|
comparator |
death (overall survival) | progression or death (progression free survival PFS) |
|
|
| Pertuzumab | advanced breast cancer (metastatic), in all type of patients | vs trastuzumab + docetaxel | by 32% | by 38% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.68 [0.56 0.83] | p=0.04 | 0 | 808 | 1 | CLEOPATRA, | | progression or death (progression free survival PFS) | 0.62 [0.51 0.75] | p=0.04 | 0 | 808 | 1 | CLEOPATRA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CLEOPATRA, 2012 | pertuzumab plus trastuzumab plus docetaxel | placebo plus trastuzumab plus docetaxel | patients with HER2-positive metastatic breast cancer | | neoSphere (Group B), 2012 | pertuzumab and trastuzumab
plus docetaxel | trastuzumab plus docetaxel | women with locally advanced, inflammatory, or early HER2-positive breast cancer |
|
| Pertuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs trastuzumab + docetaxel | by 32% | by 38% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.68 [0.56 0.83] | p=0.04 | 0 | 808 | 1 | CLEOPATRA, | | progression or death (progression free survival PFS) | 0.62 [0.51 0.75] | p=0.04 | 0 | 808 | 1 | CLEOPATRA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CLEOPATRA, 2012 | pertuzumab plus trastuzumab plus docetaxel | placebo plus trastuzumab plus docetaxel | patients with HER2-positive metastatic breast cancer | | neoSphere (Group B), 2012 | pertuzumab and trastuzumab
plus docetaxel | trastuzumab plus docetaxel | women with locally advanced, inflammatory, or early HER2-positive breast cancer |
|
| Pertuzumab | early breast cancer , in HER2 positive patients | vs placebo | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Aphinity, | | | people with operable HER2-positive eBC |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs capecitabine alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| von Minckwitz, 2009 | trastuzumab + capecitabine | capecitabine alone | Patients with HER-2-positive breast cancer that progresses during treatment with trastuzumab |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs docetaxel alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Marty, 2005 | | | patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs lapatinib alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Blackwell, 2010 | lapatinib + trastuzumab | lapatinib alone | women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Gasparini, 2006 | trastuzumab + weekly paclitaxel | weekly paclitaxel | patients with advanced breast cancer overexpressing HER-2. |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs standard chemotherapy alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Slamon, 2001 | standard chemotherapy plus trastuzumab | standard chemotherapy alone | women with metastatic breast cancer that overexpressed HER2 |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs anastrozole alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TAnDEM (Kaufman), 2009 | anastrozole (1 mg/d orally) with trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression | anastrozole | postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer |
|
| Trastuzumab | advanced breast cancer (metastatic), in all type of patients | vs letrozole alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Huober, 2012 | letrozole plus trastuzumab | letrozole alone | patients with HER2-positive, hormone-receptor-positive metastatic breast cancer |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs capecitabine alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| von Minckwitz, 2009 | trastuzumab + capecitabine | capecitabine alone | Patients with HER-2-positive breast cancer that progresses during treatment with trastuzumab |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs docetaxel alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Marty, 2005 | | | patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs lapatinib alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Blackwell, 2010 | lapatinib + trastuzumab | lapatinib alone | women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs paclitaxel alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Gasparini, 2006 | trastuzumab + weekly paclitaxel | weekly paclitaxel | patients with advanced breast cancer overexpressing HER-2. |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs standard chemotherapy alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Slamon, 2001 | standard chemotherapy plus trastuzumab | standard chemotherapy alone | women with metastatic breast cancer that overexpressed HER2 |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs anastrozole alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TAnDEM (Kaufman), 2009 | anastrozole (1 mg/d orally) with trastuzumab (4 mg/kg intravenous infusion on day 1, then 2 mg/kg every week) until progression | anastrozole | postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer |
|
| Trastuzumab | advanced breast cancer (metastatic), in HER2 positive patients | vs letrozole alone | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Huober, 2012 | letrozole plus trastuzumab | letrozole alone | patients with HER2-positive, hormone-receptor-positive metastatic breast cancer |
|
| Trastuzumab | early breast cancer , in HER2 positive patients | vs control | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| NSABP B31, 2005 | 52 weeks of trastuzumab | no trastuzumab | patients with node-positive, HER2-positive breast cancer | | BCIRG006, 2013 | | | | | Buzdar, 2005 | simultaneous weekly trastuzumab for 24 weeks | no trastuzumab | patienst with HER 2-positive operable breast cancer | | FinHer, 2006 | concomitant treatment with trastuzumab | no trastuzumab | Women with tumors that overexpressed HER2/neu | | HERA, 2005 | ??? | ??? | patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy | | N9831, 2005 | | | | | NOAH, 2010 | 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment | no trastuzumab | patients with HER2-positive locally advanced breast cancer | | PACS-04, 2009 | | | | | N9831 (1), 0 | | | | | N9831 (2), 0 | | | | | FinHer (1), 3000 | | | |
|
| Trastuzumab emtansine | advanced breast cancer (metastatic), in all type of patients | vs lapatinib plus capecitabine | by 32% | by 35% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.68 [0.55 0.85] | p=0.04 | 0 | 991 | 1 | EMILIA, | | progression or death (progression free survival PFS) | 0.65 [0.55 0.77] | p=0.04 | 0 | 991 | 1 | EMILIA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EMILIA, 2012 | Trastuzumab emtansine | lapatinib plus capecitabine | patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane |
|
| Trastuzumab emtansine | advanced breast cancer (metastatic), in all type of patients | vs usual care | - | by 47% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.53 [0.42 0.66] | p=0.04 | 0 | 602 | 1 | TH3RESA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TH3RESA, 2014 | trastuzumab emtansine | physicians choice | patients with progressive HER2-positive advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting |
|
| Trastuzumab emtansine | advanced breast cancer (metastatic), in HER2 positive patients | vs lapatinib plus capecitabine | by 32% | by 35% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | 0.68 [0.55 0.85] | p=0.04 | 0 | 991 | 1 | EMILIA, | | progression or death (progression free survival PFS) | 0.65 [0.55 0.77] | p=0.04 | 0 | 991 | 1 | EMILIA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EMILIA, 2012 | Trastuzumab emtansine | lapatinib plus capecitabine | patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane |
|
| Trastuzumab emtansine | advanced breast cancer (metastatic), in HER2 positive patients | vs usual care | - | by 47% | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.53 [0.42 0.66] | p=0.04 | 0 | 602 | 1 | TH3RESA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| TH3RESA, 2014 | trastuzumab emtansine | physicians choice | patients with progressive HER2-positive advanced breast cancer who had received two or more HER2-directed regimens in the advanced setting |
|
